Department of Endocrinology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Shandong Provincial Key Laboratory of Endocrinology and Lipid Metabolism, Institute of Endocrinology and Metabolism, Shandong Academy of Clinical Medicine, Jinan, China.
Front Endocrinol (Lausanne). 2021 Mar 2;12:578909. doi: 10.3389/fendo.2021.578909. eCollection 2021.
Previous studies have suggested that cholesterol may influence thyroid function. Since statins are widely used for their cholesterol-lowering effect, we aimed to assess the association between statin use and thyroid function, and also to explore the role of the cholesterol-lowering effect in it.
We performed a retrospective cohort study derived from REACTION study. Eligible subjects receiving statin therapy were included in the statin group, and sex-, age-, total cholesterol (TC)-, and thyroid function-matched participants without lipid-lowering therapy were included in the control group. The median follow-up time was three years. Outcomes of thyroid function were evaluated at the end of follow-up. We used multivariable regression models to assess the association between statin use and outcomes of thyroid function, and also performed mediation analyses to explore the role of cholesterol in it.
A total of 5,146 participants were screened, and 201 eligible subjects in the statin group and 201 well-matched subjects in the control group were analyzed. At the end of follow-up, TC and thyroid-stimulating hormone (TSH) levels in the statin group were lower than those in the control group (both p < 0.05), and the percentage of euthyroid subjects was higher in the statin group (88.06% vs. 76.12%, p = 0.002). The incidence rate of subclinical hypothyroidism (SCH) in euthyroid subjects was lower in the statin group (6.29% vs. 14.86%, p = 0.009), and the remission rate among subjects with SCH was higher in the statin group (50.00% vs. 15.38%, p = 0.008). In multivariable regression analyses, statin use was independently associated with lower TSH levels and higher odds to be euthyroid (OR 2.335, p = 0.004) at the end of follow-up. Mediation analyses showed the association between statin use and TSH levels were mediated by TC changes during follow-up.
Statin use was associated with benefits of thyroid function, and TC changes serve as a mediator of the association between statin use and TSH levels. Further studies are needed to clarify the possible underlying mechanism.
先前的研究表明胆固醇可能会影响甲状腺功能。由于他汀类药物被广泛用于降低胆固醇,我们旨在评估他汀类药物的使用与甲状腺功能之间的关联,并探讨其在其中的作用。
我们进行了一项来自 REACTION 研究的回顾性队列研究。纳入接受他汀类药物治疗的受试者为他汀类药物组,纳入性别、年龄、总胆固醇(TC)和甲状腺功能匹配、未接受降脂治疗的参与者为对照组。中位随访时间为 3 年。在随访结束时评估甲状腺功能的结果。我们使用多变量回归模型评估他汀类药物的使用与甲状腺功能结果之间的关联,并进行中介分析以探讨胆固醇在其中的作用。
共筛选出 5146 名参与者,其中 201 名符合他汀类药物组条件的受试者和 201 名匹配良好的对照组受试者被纳入分析。在随访结束时,他汀类药物组的 TC 和促甲状腺激素(TSH)水平低于对照组(均 p < 0.05),他汀类药物组的甲状腺功能正常者比例更高(88.06% vs. 76.12%,p = 0.002)。在甲状腺功能正常的患者中,他汀类药物组亚临床甲状腺功能减退症(SCH)的发生率较低(6.29% vs. 14.86%,p = 0.009),而 SCH 患者的缓解率较高(50.00% vs. 15.38%,p = 0.008)。在多变量回归分析中,他汀类药物的使用与 TSH 水平较低和随访结束时甲状腺功能正常的几率较高独立相关(OR 2.335,p = 0.004)。中介分析表明,他汀类药物的使用与 TSH 水平之间的关联是通过随访期间 TC 变化介导的。
他汀类药物的使用与甲状腺功能的改善有关,TC 变化是他汀类药物的使用与 TSH 水平之间关联的中介。需要进一步的研究来阐明可能的潜在机制。